Disease · MONDO_0020640
autoimmune encephalitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. autoimmune encephalitis. Diseases, record MONDO_0020640. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020640
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 3 | ClinicalTrials.gov | 4 | 4 | 1 | Drugs and targets | |
| DARATUMUMAB | CHEMBL1743007 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OFATUMUMAB | CHEMBL1201836 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BORTEZOMIB | CHEMBL325041 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EFGARTIGIMOD ALFA | CHEMBL4297551 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| INEBILIZUMAB | CHEMBL2109334 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MINOCYCLINE | CHEMBL1434 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OCRELIZUMAB | CHEMBL2108041 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ROZANOLIXIZUMAB | CHEMBL4297820 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALDESLEUKIN | CHEMBL1201438 | Protein | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets47
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| MS4A1 | B-lymphocyte antigen CD20 | 3 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| FCGRT | IgG receptor FcRn large subunit p51 | 2 | IgG receptor FcRn large subunit p51 antagonist; IgG receptor FcRn large subunit p51 inhibitor | Phase 2 | https://conductscience.org/library/genes/2217 | Drugs and targets |
| ABAT | 4-aminobutyrate aminotransferase, mitochondrial | 1 | Gamma-amino-N-butyrate transaminase inhibitor | Unknown | https://conductscience.org/library/genes/18 | Drugs and targets |
| ADRM1 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| CD19 | B-lymphocyte antigen CD19 | 1 | B-lymphocyte antigen CD19 binding agent | Phase 2 | https://conductscience.org/library/genes/930 | Drugs and targets |
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 1 | Lymphocyte differentiation antigen CD38 inhibitor | Phase 3 | https://conductscience.org/library/genes/952 | Drugs and targets |
| IL2RA | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/3559 | Drugs and targets |
| IL2RB | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/3560 | Drugs and targets |
| IL2RG | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/3561 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Unknown | https://conductscience.org/library/genes/2908 | Drugs and targets |
1 to 10 of 47
See all 47 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04875975 | A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis | Phase 2 | 12 | 2025-05-31 | Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis | ROZANOLIXIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03835728 | Efficacy of Ocrelizumab in Autoimmune Encephalitis | Phase 2 | 3 | 2021-10-19 | Autoimmune Encephalitis | OCRELIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06867991 | Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis | Phase 3 | 200 | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | DARATUMUMAB, OFATUMUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04372615 | The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis | Phase 2 | 116 | Autoimmune Encephalitis, Encephalitis | INEBILIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03542279 | CPI Combination Therapy for Autoimmune Encephalitis | Not applicable | 70 | Autoimmune Encephalitis | METHYLPREDNISOLONE | Its record names the disease | ClinicalTrials.gov | |
| NCT06033846 | Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis | Phase 2 | 60 | Autoimmune Encephalitis | MINOCYCLINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03993262 | Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis | Phase 2 | 50 | Autoimmune Encephalitis | BORTEZOMIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05177939 | Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis | Phase 3 | 40 | Autoimmune Encephalitis | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov | |
| NCT03530462 | To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI | 22 | Cognitive Impairment, Autoimmune Encephalitis | CYCLOPHOSPHAMIDE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT02714959 | IL-2 in Refractory Autoimmune Encephalitis | Phase 1/2 | 10 | Encephalitis | ALDESLEUKIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rozanolixizumab (RLZ) vs Placebo: deaths from any cause | 0 of 6 | 0 of 6 | 12 | NCT04875975 | Trial comparisons |
| Rozanolixizumab (RLZ) vs Placebo: Number of Participants Who Required Rescue Medication Due to an Absence or Loss of Clinical Benefit During the Treatment | 2 of 6 | 3 of 6 | 12 | NCT04875975 | Trial comparisons |
| Rozanolixizumab (RLZ) vs Placebo: Number of Seizure Free Study Participants at the End of the Treatment | 0 of 6 | 1 of 6 | 12 | NCT04875975 | Trial comparisons |
| Rozanolixizumab (RLZ) vs Placebo: serious adverse events | 3 of 6 | 3 of 6 | 12 | NCT04875975 | Trial comparisons |
| Treatment Arm vs Treatment Placebo Arm: deaths from any cause | 0 of 2 | 0 of 1 | 3 | NCT03835728 | Trial comparisons |
| Treatment Arm vs Treatment Placebo Arm: Number of Participants Who Had Clinical Worsening | 0 of 2 | 1 of 1 | 3 | NCT03835728 | Trial comparisons |
| Treatment Arm vs Treatment Placebo Arm: serious adverse events | 0 of 2 | 0 of 1 | 3 | NCT03835728 | Trial comparisons |
Papers from its trials43
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020640
GET https://conductscience.org/api/diseases/v1/MONDO_0020640/targets?page=2